LGM
EPRX

Logos Global Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Logos Global Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-900,000
Closed -$5.31M – 83
2025
Q3 		$5.31M Buy
+900,000
New +$4.9M 0.48% 47

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

Logos Global Management's EPRX Position: Q4 2025 in Review

Logos Global Management sold out of Eupraxia Pharmaceuticals (EPRX) in Q4 2025, closing a stake of 900,000 shares — an estimated $5.31M sold.

Logos Global Management first reported a position in EPRX in Q3 2025 and held it in 1 quarter. The position peaked at $5.31M in Q3 2025. 35 funds tracked by Wall St. Rank hold EPRX as of Q4 2025.

  • Logos Global Management reported no remaining Eupraxia Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Logos Global Management sold 900,000 Eupraxia Pharmaceuticals shares in Q4 2025, an estimated $5.31M.
  • Logos Global Management first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Logos Global Management's Eupraxia Pharmaceuticals position peaked at $5.31M in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q4 2025.

Based on Logos Global Management's 13F filing for Q4 2025, filed 17 Feb 2026.